Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

skyrockets_Inc Jun. 30 at 6:35 PM

$VTGN I got out at 0.32 in the pre-market after the halt. Not sure how they are planning to continue another P3 trial w/ a 9m market cap currently. Dilution seems impossible to raise anything meaningful....reverse split imminent. I don't see a path forward here that doesn't burn all remaining cash unless a miracle partner/buyout happens but that's than 5% chance in my eyes. I cut my 100k loss and moved on to $HOWL

1 · Reply

longshot45 Jun. 30 at 2:21 PM

$HOWL looks like yesterdays MPM filing should 0 out their position. Timing makes sense as today ends the quarter. Ironically does not make sense as the critical trial ends next month as does the initial delist notice. This saga should be over within 2 months one way or the other now.

1 · Reply

Orlandotrader Jun. 29 at 7:31 PM

$HOWL They’re Flushing the Toilet on this Giant Turd!!!!

1 · Reply

LabPsycho Jun. 29 at 2:11 PM

$HOWL @longshot45 Good detective work and post. I would expect, like BCAB did ~9 months ago, one last gasp / faux pump before / around the time of R/S. Good luck

2 · Reply

longshot45 Jun. 24 at 3:02 PM

$HOWL I’m a little surprised we have not seen a lawsuit filed by RA Capital investors given the fact they waited until MPM sold their entire position and depressed the stock from about 1.5 down to the mid .30s before they started heavy duty selling themselves. Basically a wealth transfer from RA Capital shareholders to MPM. Still sucks for Howl owners but nothing we can do about that

1 · Reply

Arthur86 Jun. 24 at 2:52 PM

$HOWL

0 · Reply

zawojak Jun. 23 at 9:18 AM

$HOWL more heavy sales from RA ...guess howl staff will burn cash with their salaries after which they will pink sheet it. Classic move for bad managed bio business. Just my opinion.

0 · Reply

longshot45 Jun. 17 at 4:02 PM

$HOWL RA is still selling, so definitely not just trying to get to 9.9%. I have to question if they and MPM have access to info that is not public… Take a look at clinicaltrials NCT05479812 Study ends July 2026… so I fear these guy have access to see the current results before the study is even completed.

1 · Reply

Lyn30 Jun. 17 at 1:46 PM

$HOWL Bought some yesterday. Will add more if goes down. 1/3 is done 2/3 rd next

0 · Reply

skyrockets_Inc Jun. 16 at 6:50 PM

$HOWL Good explanation on why RA is likely dropping to 9.9% exactly. You see this all the time in other tickers as well. It's not necessarily a bad thing. Gives them more flexibility to sell when news finally does drop.

1 · Reply

Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates

May 7, 2026, 7:00 AM EDT - 2 months ago

Werewolf Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Werewolf Therapeutics Earnings release: Q1 2026

2026-03-27T11:16:02.000Z - 3 months ago

Werewolf Therapeutics hires Piper Sandler to assist in strategic evaluation

2026-03-27T11:15:46.000Z - 3 months ago

Werewolf Therapeutics reports Q4 EPS (20c), consensus (35c)

2026-03-27T11:10:27.000Z - 3 months ago

Werewolf Therapeutics to explore range of strategic alternatives

Mar 27, 2026, 7:00 AM EDT - 3 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

Mar 27, 2026, 7:00 AM EDT - 3 months ago

Werewolf Therapeutics Annual report: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 3 months ago

Werewolf Therapeutics Earnings release: Q4 2025

2026-02-25T00:40:12.000Z - 4 months ago

Werewolf Therapeutics to explore strategic alternatives

2026-02-24T21:51:46.000Z - 4 months ago

Werewolf Therapeutics trading resumes

2026-02-24T21:10:20.000Z - 4 months ago

Werewolf Therapeutics trading halted, news pending

Feb 24, 2026, 4:09 PM EST - 4 months ago

Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives

2026-02-13T21:30:19.000Z - 5 months ago

Werewolf Therapeutics announces 64% workforce reduction

2025-12-19T15:35:48.000Z - 7 months ago

Citizens downgrades Werewolf Therapeutics on need for capital

2025-12-19T15:30:17.000Z - 7 months ago

Werewolf Therapeutics downgraded to Market Perform from Outperform at Citizens

2025-12-19T14:35:19.000Z - 7 months ago

Wedbush downgrades Werewolf Therapeutics to Neutral on challenging path

2025-12-19T14:30:52.000Z - 7 months ago

Werewolf Therapeutics downgraded to Neutral from Outperform at Wedbush

2025-12-19T12:55:46.000Z - 7 months ago

Werewolf Therapeutics price target lowered to $4 from $10 at H.C. Wainwright

2025-12-18T13:20:39.000Z - 7 months ago

Werewolf Therapeutics provides pipeline update, review of INDUKINE data

2025-12-18T13:20:21.000Z - 7 months ago

Werewolf Therapeutics announces 2025 priorities

Dec 18, 2025, 8:00 AM EST - 7 months ago

Werewolf Therapeutics Announces Pipeline and Business Updates

2025-11-18T14:43:22.000Z - 8 months ago

Werewolf Therapeutics price target lowered to $7 from $8 at BofA

2025-11-07T14:15:14.000Z - 8 months ago

Werewolf Therapeutics presents preclinical data on PREDATOR Platform

Nov 7, 2025, 9:00 AM EST - 8 months ago

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Nov 4, 2025, 4:00 PM EST - 8 months ago

Werewolf Therapeutics Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 8 months ago

Werewolf Therapeutics Quarterly report: Q3 2025

2025-11-04T12:16:23.000Z - 8 months ago

Werewolf Therapeutics reports Q3 EPS (36c), consensus (38c)

Nov 4, 2025, 7:00 AM EST - 8 months ago

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-08T12:06:01.000Z - 9 months ago

Werewolf Therapeutics receives FTD from U.S. FDA for WTX-124

Oct 8, 2025, 8:00 AM EDT - 9 months ago

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

Oct 3, 2025, 9:00 AM EDT - 9 months ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Sep 8, 2025, 2:00 PM EDT - 10 months ago

Werewolf Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 10 months ago

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

2025-08-25T11:10:16.000Z - 11 months ago

Werewolf Therapeutics price target lowered to $8 from $9 at BofA

2025-08-21T09:45:12.000Z - 11 months ago

Werewolf Therapeutics price target lowered to $3 from $4 at Citizens JMP

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Werewolf Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:00 AM EDT - 11 months ago

Werewolf Therapeutics Quarterly report: Q2 2025

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 1 year ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 14, 2025, 6:15 PM EDT - 1 year ago

Werewolf Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 10:00 AM EDT - 1 year ago

Werewolf Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Registration statement: Registration Filing

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Slides: Corporate Presentation

May 5, 2025, 8:05 AM EDT - 1 year ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Apr 7, 2025, 1:30 PM EDT - 1 year ago

Werewolf Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 11:20 AM EDT - 1 year ago

Werewolf Therapeutics Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Annual report: Q4 2024

Mar 4, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 1 year ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Dec 5, 2024, 12:30 PM EST - 1 year ago

Werewolf Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 20, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 11:00 AM EST - 1 year ago

Werewolf Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 11:00 AM EST - 1 year ago

Werewolf Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 9:02 AM EST - 1 year ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 11:00 AM EDT - 2 years ago

Werewolf Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 11:00 AM EDT - 2 years ago

Werewolf Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:05 AM EDT - 2 years ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 25, 2024, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Transcript: Study Update

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Slides: Study Update

Jun 1, 2024, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 2 years ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Quarterly report: Q1 2024

May 3, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Earnings release: Q1 2024

May 3, 2024, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 2 years ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Werewolf Therapeutics Proxy statement: Proxy Filing

Apr 5, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:30 PM EDT - 2 years ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Annual report: Q4 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Earnings release: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 2 years ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 2 years ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Nov 22, 2023, 7:00 AM EST - 2 years ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 2 years ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 14, 2023, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Quarterly report: Q3 2023

Nov 14, 2023, 8:00 AM EST - 2 years ago

Werewolf Therapeutics Earnings release: Q3 2023

Nov 3, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Slides: Investor Presentation

Nov 3, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 3 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 3 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Werewolf Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Werewolf Therapeutics Earnings release: Q2 2023

Aug 10, 2023, 7:10 AM EDT - 3 years ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 7:00 AM EDT - 3 years ago

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

skyrockets_Inc Jun. 30 at 6:35 PM

1 · Reply

longshot45 Jun. 30 at 2:21 PM

1 · Reply

Orlandotrader Jun. 29 at 7:31 PM

$HOWL They’re Flushing the Toilet on this Giant Turd!!!!

1 · Reply

LabPsycho Jun. 29 at 2:11 PM

$HOWL @longshot45 Good detective work and post. I would expect, like BCAB did ~9 months ago, one last gasp / faux pump before / around the time of R/S. Good luck

2 · Reply

longshot45 Jun. 24 at 3:02 PM

1 · Reply

Arthur86 Jun. 24 at 2:52 PM

$HOWL

0 · Reply

zawojak Jun. 23 at 9:18 AM

$HOWL more heavy sales from RA ...guess howl staff will burn cash with their salaries after which they will pink sheet it. Classic move for bad managed bio business. Just my opinion.

0 · Reply

longshot45 Jun. 17 at 4:02 PM

1 · Reply

Lyn30 Jun. 17 at 1:46 PM

$HOWL Bought some yesterday. Will add more if goes down. 1/3 is done 2/3 rd next

0 · Reply

skyrockets_Inc Jun. 16 at 6:50 PM

1 · Reply

BiotechValues Jun. 16 at 4:44 PM

$HOWL RA should be almost done selling. They got their main fund down to 9.9% exactly, no coincidence. The other fund has about 300k left.

0 · Reply

Lyn30 Jun. 16 at 2:59 PM

$HOWL Watching this one for good entry

0 · Reply

BiotechValues Jun. 16 at 2:27 PM

$HOWL if I had to guess RA is trying to drop to under 10% ownership reporting requirements. If you look at 13d yesterday one of their funds is now exactly 9.9%..

1 · Reply

zawojak Jun. 16 at 12:17 PM

$HOWL RA Capital Management just dumped 16% of their ownership. I had a little hope now more likely this will go ponk sheetz. Just my opinion.

1 · Reply

longshot45 Jun. 15 at 3:14 PM

$HOWL So now RA capital is offloading more shares? Why would they have waited for MPM to basically sell out everything they had before making a major move like that? It makes little sense. Does not bode well for any of us long term shareholders

1 · Reply

barney00 Jun. 12 at 5:57 PM

$HOWL is this thing dead…a lost cause?

0 · Reply

skyrockets_Inc Jun. 11 at 6:48 PM

$HOWL I added 200k shares today. Will add more if it drops to low 30s. Ready for lift-off.

1 · Reply

skyrockets_Inc Jun. 9 at 6:54 PM

$HOWL Will it get to low 30s while tutes are still off-loading? Entry point here still not terrible.

0 · Reply

CautiousInvestor1929 Jun. 9 at 3:57 PM

$HOWL watching carefully from the sidelines for an entry here

1 · Reply

Gottfried777 Jun. 9 at 3:22 PM

$HOWL I have 450 shares @ 1.02 😂

1 · Reply

zawojak Jun. 3 at 8:59 PM

$HOWL RIP

1 · Reply

longshot45 May. 28 at 11:25 PM

$HOWL Another filing by MPM to sell. Looks like about 30% of their remaining stock, so they should be out completely in say a month… Then july we should get some updates trial results. Though I do wonder if a reverse split is in the works

0 · Reply

Market Cap	16.54M
Revenue (ttm)	0.00
Net Income (ttm)	-60.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	683,900
Avg Vol	692,686
Day's Range	N/A - N/A
Shares Out	48.60M
Stochastic %K	63%
Beta	0.30
Analysts	Strong Sell
Price Target	$6.00